Zelapar is a drug owned by Bausch Health Us Llc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 01, 2016. Details of Zelapar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6423342 | Process for the preparation of a solid pharmaceutical dosage form |
Mar, 2016
(8 years ago) |
Expired
|
| US5648093 | Pharmaceutical and other dosage forms |
Jul, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Zelapar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zelapar's family patents as well as insights into ongoing legal events on those patents.
Zelapar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zelapar's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 01, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zelapar Generic API suppliers:
Selegiline Hydrochloride is the generic name for the brand Zelapar. 11 different companies have already filed for the generic of Zelapar, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zelapar's generic
About Zelapar
Zelapar is a drug owned by Bausch Health Us Llc. It is used for treating hypertension and heart failure. Zelapar uses Selegiline Hydrochloride as an active ingredient. Zelapar was launched by Bausch in 2006.
Approval Date:
Zelapar was approved by FDA for market use on 14 June, 2006.
Active Ingredient:
Zelapar uses Selegiline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Selegiline Hydrochloride ingredient
Treatment:
Zelapar is used for treating hypertension and heart failure.
Dosage:
Zelapar is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.25MG | TABLET, ORALLY DISINTEGRATING | Prescription | ORAL |